↓ Skip to main content

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Overview of attention for article published in Blood, September 2012
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

policy
1 policy source
twitter
3 X users

Citations

dimensions_citation
125 Dimensions

Readers on

mendeley
77 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Published in
Blood, September 2012
DOI 10.1182/blood-2012-06-436725
Pubmed ID
Authors

Ulrike Bacher, Evgeny Klyuchnikov, Jennifer Le-Rademacher, Jeanette Carreras, Philippe Armand, Michael R. Bishop, Christopher N. Bredeson, Mitchell S. Cairo, Timothy S. Fenske, Cesar O. Freytes, Robert Peter Gale, John Gibson, Luis M. Isola, David J. Inwards, Ginna G. Laport, Hillard M. Lazarus, Richard T. Maziarz, Peter H. Wiernik, Harry C. Schouten, Shimon Slavin, Sonali M. Smith, Julie M. Vose, Edmund K. Waller, Parameswaran N. Hari

Abstract

The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified. We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC; n = 165), reduced intensity (RIC; n = 143), or nonmyeloablative conditioning (NMAC; n = 88) regimens. Acute and chronic GVHD rates were similar across the groups. Five-year nonrelapse mortality (NRM) was higher in MAC than RIC and NMAC (56% vs 47% vs 36%; P = .007). Five-year relapse/progression was lower in MAC than in RIC/NMAC (26% vs 38% vs 40%; P = .031). Five-year progression-free survival (15%-25%) and overall survival (18%-26%) did not differ significantly between the cohorts. In multivariate analysis, NMAC and more recent transplant year were associated with lower NRM, whereas a lower Karnofsky performance score (< 90), prior relapse resistant to therapy, and use of unrelated donors were associated with higher NRM. NMAC transplants, no prior use of rituximab, and prior relapse resistant to therapy were associated with a greater risk of relapse/progression. In conclusion, allotransplantation with RIC or NMAC induces long-term progression-free survival in selected DLBCL patients with a lower risk of NRM but with higher risk of lymphoma progression or relapse.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 3 4%
Spain 1 1%
United States 1 1%
Unknown 72 94%

Demographic breakdown

Readers by professional status Count As %
Other 18 23%
Researcher 15 19%
Professor > Associate Professor 13 17%
Student > Postgraduate 4 5%
Student > Doctoral Student 3 4%
Other 12 16%
Unknown 12 16%
Readers by discipline Count As %
Medicine and Dentistry 42 55%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Nursing and Health Professions 3 4%
Biochemistry, Genetics and Molecular Biology 2 3%
Agricultural and Biological Sciences 2 3%
Other 6 8%
Unknown 18 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2016.
All research outputs
#6,997,226
of 25,374,647 outputs
Outputs from Blood
#12,317
of 33,239 outputs
Outputs of similar age
#51,304
of 190,204 outputs
Outputs of similar age from Blood
#92
of 304 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 33,239 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 190,204 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 304 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.